Aclaris Therapeutics reported a net loss of $59.8 million for the nine months ended September 30, 2026, compared to $45.1 million for the same period in 2025. The company significantly increased its cash position through at-the-market sales of common stock, raising approximately $116.2 million in net proceeds during the first nine months of 2026.
Aclaris Therapeutics reported its Q3 2026 financial results, highlighting a cash position of $156.4M which is expected to fund operations through the first half of 2029. The company also provided clinical updates, including positive Phase 1b data for ATI-052 in atopic dermatitis and asthma, and the planned initiation of a Phase 2b trial for modzatinib in the fourth quarter of 2026.
Term
Q3 2026
“Aclaris is developing unique product candidates designed to provide improved therapeutic options across a variety of inflammatory disorders with the goal of raising the efficacy ceiling, and our recent progress reflects continued execution toward that objective.”
Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris